Renaissance Technologies’s Candel Therapeutics CADL Stock Holding History

Renaissance Technologies’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.6K	Buy	+12,780	New	+$69.5K	﹤0.01%	3088
2025 Q3	–	Sell	-163,600	Closed	-$828K	–	3532
2025 Q2	$828K	Buy	+163,600	New	+$842K	﹤0.01%	2597
2024 Q3	–	Sell	-20,600	Closed	-$128K	–	3548
2024 Q2	$128K	Sell	20,600 -36,305	-64%	-$272K	﹤0.01%	3140
2024 Q1	$90K	Buy	56,905 +38,230	+205%	+$56.8K	﹤0.01%	3390
2023 Q4	$27K	Buy	+18,675	New	+$18.1K	﹤0.01%	3543
2023 Q3	–	Sell	-12,800	Closed	-$16K	–	3696
2023 Q2	$16K	Sell	12,800 -8,200	-39%	-$12.1K	﹤0.01%	3795
2023 Q1	$28K	Buy	+21,000	New	+$41K	﹤0.01%	3766

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies's CADL Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Candel Therapeutics (CADL) in Q1 2026: 12,780 shares worth $62.6K. The stake represents ﹤0.01% of the portfolio and ranks #3088 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in CADL as recently as Q2 2025.

Renaissance Technologies first reported a position in CADL in Q1 2023 and has held it in 7 quarters since. The position peaked at $828K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Renaissance Technologies held 12,780 shares of Candel Therapeutics worth $62.6K as of Q1 2026.
Candel Therapeutics was a new Renaissance Technologies position in Q1 2026.
Candel Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3088 holding.
Renaissance Technologies first reported a position in Candel Therapeutics in Q1 2023 and has held it in 7 quarters since.
Renaissance Technologies's Candel Therapeutics position peaked at $828K in Q2 2025.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.